$135,00
Triple agonist (GIP/GLP‑1/glucagon receptors) investigated in obesity and metabolic‑disease research.
Each component contributes differently. GLP-1 reduces appetite, slows gastric emptying and improves glucose regulation. GIP contributes to insulin regulation and may complement GLP-1’s effects. Glucagon-receptor agonism is the unusual part—it may increase energy expenditure and alter substrate/fat metabolism in addition to appetite suppression.

Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors[1], studied for substantial weight loss and metabolic improvement in obesity and type 2 diabetes[2][3]. With an extended half-life of approximately 6 days, this peptide enables convenient once-weekly subcutaneous dosing with a gradual titration protocol to optimize tolerability[1][4].
Technical Specifications:
Synonyms: LY3437943
Chemical Formula: C₂₄H₃₄Cl₂N₆O₄
CAS Number: 2381089-83-2
Molecular Weight: Approx. 5,534 g/mol
Purity: ≥99.0% (validated by Certificate of Analysis)
Appearance: White to off-white lyophilized powder
Peptide Length: 39 amino acids
Solubility: Fully soluble in water (H₂O)
Quality Verification: Confirmed by RP-HPLC analysis
Storage Conditions: Store dry at 2–8 °C; reconstituted material refrigerated and used within 6 weeks
Source: https://peptidedosages.com/single-peptide-dosages/retatrutide-20-mg-vial-dosage-protocol/
Research Use Only: Not for human or veterinary use.

99% PURITY

FAST DELIVERY

SSL ENCRYPTED

NOT FOR HUMAN USE

Research pathways for tissue repair

Supports training and output

Lab tested a 99% purity

For laboratory research only
Tracking Number
100% private delivery
SSL encrypted
We stand by our products